Sumitomo Dainippon Pharma Co Ltd (JP:4506)
:4506
Want to see JP:4506 full AI Analyst Report?
4506 Stock Chart & Stats
¥1854.50
¥4.00(0.72%)
At close: 4:00 PM EST
¥1854.50
¥4.00(0.72%)
Day’s Range― - ―
52-Week Range¥744.00 - ¥3,288.00
Previous CloseN/A
Volume1.08M
Average Volume (3M)5.45M
Market Cap
¥777.86B
Enterprise Value¥862.52B
Total Cash (Recent Filing)¥44.31B
Total Debt (Recent Filing)¥217.19B
Price to Earnings (P/E)7.7
Beta1.24
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding449,204,560
10 Day Avg. Volume5,265,230
30 Day Avg. Volume5,454,233
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.82
Price to Sales (P/S)1.82
P/FCF Ratio12.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Profitability Turnaround (2026)The sharp recovery in operating profitability and net margin in 2026 indicates restored core earnings power and improved unit economics. Sustained margins enhance cash generation capacity, support R&D funding and commercialization, and provide a more durable base for reinvestment and strategic partnerships over the next several quarters.
Improved Leverage And Balance-sheet RepairMaterial deleveraging in 2026 meaningfully reduces refinancing and solvency risk, increasing financial flexibility. A stronger capital structure supports sustained investment in R&D, potential M&A or licensing deals, and lowers interest burden, making operations more resilient to cyclical pressures over the medium term.
Stronger Free Cash Flow And ConversionImproved free cash flow and higher conversion from net income signal better cash quality of earnings, enabling self-funded product development, commercialization, and balance-sheet repair. Durable FCF supports strategic options (licensing, partnerships) and reduces dependence on external financing in the coming 2–6 months.
Bears Say
Revenue Volatility And Top-line InstabilityLarge swings in revenue undermine predictability of earnings and cash flow, complicating long-term planning for R&D, launches and commercial investments. Persistent top-line instability suggests dependence on a few products or markets and raises execution risk for sustaining growth over the next several quarters.
Inconsistent Cash Generation HistoryHistorical cash-flow swings, including a large outflow in 2024, reduce confidence in ongoing ability to self-fund operations and investments. Even with 2026 improvement, intermittent coverage raises the risk that unexpected costs or slower sales could force external financing or defer strategic programs within a 2–6 month horizon.
Prior Elevated Leverage And Asset DeclinesLegacy periods of high leverage and shrinking asset base increase vulnerability to future shocks and limit strategic optionality. Remaining balance-sheet after-effects may constrain investment cadence, push management toward conservative cash uses, or necessitate asset disposals or dilutive financing if headwinds re-emerge.
Sumitomo Dainippon Pharma Co News
4506 FAQ
What was Sumitomo Dainippon Pharma Co Ltd’s price range in the past 12 months?
Sumitomo Dainippon Pharma Co Ltd lowest stock price was ¥744.00 and its highest was ¥3288.00 in the past 12 months.
What is Sumitomo Dainippon Pharma Co Ltd’s market cap?
Sumitomo Dainippon Pharma Co Ltd’s market cap is ¥777.86B.
When is Sumitomo Dainippon Pharma Co Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Sumitomo Dainippon Pharma Co Ltd’s earnings last quarter?
Currently, no data Available
Is Sumitomo Dainippon Pharma Co Ltd overvalued?
According to Wall Street analysts Sumitomo Dainippon Pharma Co Ltd’s price is currently Overvalued.
Does Sumitomo Dainippon Pharma Co Ltd pay dividends?
Sumitomo Dainippon Pharma Co Ltd pays a Semiannually dividend of ¥7 which represents an annual dividend yield of N/A. See more information on Sumitomo Dainippon Pharma Co Ltd dividends here
What is Sumitomo Dainippon Pharma Co Ltd’s EPS estimate?
Sumitomo Dainippon Pharma Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sumitomo Dainippon Pharma Co Ltd have?
Sumitomo Dainippon Pharma Co Ltd has 449,204,560 shares outstanding.
What happened to Sumitomo Dainippon Pharma Co Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sumitomo Dainippon Pharma Co Ltd?
Currently, no hedge funds are holding shares in JP:4506
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
4506 Company Deck
4506 Earnings Call
Q3 2026
0:00 / 0:00
Technical Analysis
Eisai Co
―
Kissei Pharmaceutical Co
―
Shionogi & Co
―
Takeda Pharmaceutical Co
―
Nippon Shinyaku Co., Ltd.
―
Options Prices
Currently, No data available
---